Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kipp Weiskopf

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Investigation|February 14, 2012
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancerHolbrook E Kohrt, Roch Houot, Kipp Weiskopf, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2012
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcomaBadreddin Edris, Kipp Weiskopf, Anne K Volkmer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2013
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthBadreddin Edris, Stephen B Willingham, Kipp Weiskopf, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
CD47 predominates over CD24 as a macrophage immune checkpoint in cancerJuliet Allen, Anna Meglan, Kyle Vaccaro, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2017
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activityNan Guo Ring, Dietmar Herndler-Brandstetter, Kipp Weiskopf, et al.
Cancer Immunology Research|November 19, 2016
Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20Kipp Weiskopf, Katie L Anderson, Daisuke Ito, et al.
Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.
Nature Immunology|November 29, 2017
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapyAmira A Barkal, Kipp Weiskopf, Kevin S Kao, et al.
Cell Reports|September 10, 2023
MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosisVaishnavi V Phadnis, Jamie Snider, Venkateshwari Varadharajan, et al.
The Journal of Clinical Investigation|May 20, 2014
Targeting CD137 enhances the efficacy of cetuximabHolbrook E Kohrt, A Dimitrios Colevas, Roch Houot, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Investigation|February 14, 2012
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancerHolbrook E Kohrt, Roch Houot, Kipp Weiskopf, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2012
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcomaBadreddin Edris, Kipp Weiskopf, Anne K Volkmer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2013
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthBadreddin Edris, Stephen B Willingham, Kipp Weiskopf, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
CD47 predominates over CD24 as a macrophage immune checkpoint in cancerJuliet Allen, Anna Meglan, Kyle Vaccaro, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2017
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activityNan Guo Ring, Dietmar Herndler-Brandstetter, Kipp Weiskopf, et al.
Cancer Immunology Research|November 19, 2016
Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20Kipp Weiskopf, Katie L Anderson, Daisuke Ito, et al.
Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.
Nature Immunology|November 29, 2017
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapyAmira A Barkal, Kipp Weiskopf, Kevin S Kao, et al.
Cell Reports|September 10, 2023
MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosisVaishnavi V Phadnis, Jamie Snider, Venkateshwari Varadharajan, et al.
The Journal of Clinical Investigation|May 20, 2014
Targeting CD137 enhances the efficacy of cetuximabHolbrook E Kohrt, A Dimitrios Colevas, Roch Houot, et al.
Pageof 5